Armata Pharmaceuticals, Inc.
ARMP
$5.64
-$0.35-5.81%
AMEX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.05M | 6.87M | 4.70M | 5.17M | 5.47M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.05M | 6.87M | 4.70M | 5.17M | 5.47M |
| Cost of Revenue | 19.87M | 23.53M | 23.69M | 26.28M | 25.75M |
| Gross Profit | -14.82M | -16.66M | -18.99M | -21.10M | -20.29M |
| SG&A Expenses | 12.31M | 12.44M | 13.26M | 13.18M | 13.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.40M | 42.20M | 45.10M | 47.61M | 46.94M |
| Operating Income | -33.35M | -35.33M | -40.40M | -42.44M | -41.48M |
| Income Before Tax | -46.90M | -25.71M | -426.00K | -18.92M | -41.36M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -46.90 | -25.71 | -0.43 | -18.92 | -41.36 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.90M | -25.71M | -426.00K | -18.92M | -41.36M |
| EBIT | -33.35M | -35.33M | -40.40M | -42.44M | -41.48M |
| EBITDA | -31.86M | -33.89M | -39.02M | -41.11M | -40.24M |
| EPS Basic | -1.30 | -0.71 | -0.01 | -0.52 | -1.15 |
| Normalized Basic EPS | -0.83 | -0.84 | -0.90 | -0.91 | -0.86 |
| EPS Diluted | -1.91 | -1.32 | -1.12 | -1.62 | -1.64 |
| Normalized Diluted EPS | -0.66 | -0.66 | -0.64 | -0.72 | -0.77 |
| Average Basic Shares Outstanding | 144.79M | 144.74M | 144.70M | 144.64M | 144.56M |
| Average Diluted Shares Outstanding | 190.98M | 190.93M | 212.99M | 189.63M | 166.65M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |